Abakkus Asset Managers, founded by market veteran Sunil Singhania, has acquired additional shares worth ₹101 crore in pharmaceutical company Jubilant Pharmova, while Quant Mutual Fund exited Jubilant Pharmova by selling its remaining shares through open-market transactions on October 12. According to reports from The Hindu BusinessLine, Jubilant Pharmova shares fell 2.32 percent to ₹928.80 on the NSE on Tuesday, following the execution of the transaction. The latest data shows Quant Mutual Fund sold 11 lakh shares, representing 0.69 percent of Jubilant Pharmova's paid-up equity, at an average price of ₹915 per share, taking the deal value to ₹100.65 crore. This transaction represents a significant shift in institutional ownership, with Quant Small Cap Fund previously holding 29.47 lakh shares, representing a 1.85 percent stake as of June 30, 2026.
Abakkus Four2Eight Opportunities Fund purchased 11 lakh shares, representing 0.69 percent of Jubilant Pharmova's paid-up equity, from Quant Mutual Fund for ₹100.65 crore. The shares were bought at ₹915 apiece. As reported by The Hindu BusinessLine, Quant Mutual Fund sold a total of 20.81 lakh shares in the pharmaceutical company, with the additional 9.81 lakh shares sold for ₹89.82 crore at ₹915.01 per share. The total sale represented approximately 1.3 percent of the company's paid-up equity. This transaction represents a significant shift in institutional ownership, with Quant Small Cap Fund previously holding 29.47 lakh shares, representing a 1.85 percent stake as of June 30, 2026. The stake sale reduced Quant MF's holding in Jubilant Pharmova to 1.16 percent from 1.85 percent, while Abakkus Asset Manager's holding increased to 1.84 percent from 1.15 percent.
According to the shareholding pattern for the quarter ended June 2026, as reported by Moneycontrol, Abakkus Emerging Opportunities Fund-1 held a 1.15 percent stake in Jubilant Pharmova, while Quant Mutual Fund, through Quant Small Cap Fund, held a 1.85 percent stake. The transaction represents a significant shift in institutional ownership of the pharmaceutical company. Quant Small Cap Fund held 29.47 lakh shares, representing a 1.85 percent stake as of June 30, 2026. Assuming both reported sales came entirely from this holding, with no intervening changes, its holding would decline to approximately 0.54 percent of the company. The latest data shows Abakkus Asset Manager's increased holding to 1.84 percent from 1.15 percent.
Jubilant Pharmova informed the exchanges that its board had approved the issuance of up to ₹800 crore in non-convertible debentures (NCDs), with a face value of ₹1 lakh each, aggregating up to ₹800 crore. According to a regulatory filing, the board approved the issue of up to 80,000 fully paid-up, rupee-denominated, secured or unsecured, rated, listed, redeemable, and transferable NCDs of face value ₹1,00,000 each in one or more tranches, subject to applicable laws and regulatory approvals. The debentures are proposed to be listed on the BSE and carry a tenure of up to five years from the deemed date of allotment, with the coupon or interest rate to be determined during the bidding process. The board also approved seeking shareholders' authorisation through a special resolution by postal ballot to issue non-convertible debt securities on a private placement basis, for an aggregate amount not exceeding ₹2,500 crore outstanding at any point during the one year following the passing of the resolution.
Qualcomm Ventures, through its affiliate Qualcomm Asia Pacific Pte Ltd, sold a little over 57.13 lakh shares in Shadowfax Technologies, representing a 0.98 percent stake, for ₹157.28 crore. The shares were sold at an average price of ₹275.30 per share, as reported by The Hindu BusinessLine. At the end of the June quarter, Qualcomm Asia Pacific Pte Ltd owned a 2.26 percent stake in the company, according to shareholding data on the exchange. Details of the buyers could not be identified. Shadowfax Technologies shares ended marginally lower at ₹294.75 apiece on the BSE. This follows an earlier transaction in August when Qualcomm Ventures sold a 1.3 percent stake for ₹184 crore.
